Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 504-509

  Kwon, H C ^a   Roh, M S ^a   Oh, S Y ^a   Kim, S H ^a   Kim, M C ^a   Kim, J S ^a   Kim, H J ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

ERCC1; Gastric Cancer; Oxaliplatin

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; STOMACH SURGERY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33847645479     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl430     Document Type: Article

References (36)

1. Shin HR, Won YJ, Jung KW et al. 2001 Annual report of the Korea central cancer registry: Based on registration data from 134 hospitals. Cancer Res Treat 2004; 36: 19-30.
2. Douglass HO, Nava DR. Gastric adenocarcinoma: Management of the primary disease. Semin Oncol 2002; 12: 32-45.
3. Dickson JL, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004; 16: 255-263.
4. Shin JM, Kim HJ, Kim JS. Combination chemotherapy with 5-fluorouracil and cisplatin for advanced gastric cancer. Korean J Med 1993; 45: 482-489.
5. Lee WS, Lee GW, Kim HW, et al. A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer. Cancer Res Treat 2005; 37: 208-211.
6. Arnould S, Hennebelle I, Canal P et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39: 112-119.
7. Marchetti P, Galla DA, Russo FP et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 2004; 24: 219-226.
8. Mamenta EL, Poma EE, Kaufmann WK et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500-3505.
9. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
10. Goldberg RM, Sargent DJ, Morton RF et al. Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
11. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III Trial. J Clin Oncol 2003; 21: 2059-2069.
12. Kim DY, Kim JH, Lee SH et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14: 383-387.
13. Suh SH, Kwon HC, Jo JH et al. Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (Modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. Cancer Res Treat 2005; 37: 279-283.
14. De Vita F, Orditura M, Matano E et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649.
15. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of an in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980; 30: 151-169.
16. Houtsmuller AB, Rademakers S, Nigg AL et al. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 1999; 284: 958-961.
17. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304.
18. Yeh KH, Shun CT, Chen CL et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82: 1626-1631.
19. Choi J, Lim H, Nam DK et al. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001; 84: 186-192.
20. Lenz HJ, Leichman CG, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182.
21. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-4320.
22. Moscow JA, Fairchild CR, Madden MJ et al. Expression of anionic glutathione-Stransferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422-1428.
23. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337-384.
24. Goto S, Iida T, Cho S et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999; 31: 549-558.
25. Bai F, Nakanishi Y, Kawasaki M et al. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 1996; 78: 416-421.
26. Raymond E, Faivre S, Chaney S et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-235.
27. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291.
28. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304.
29. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
30. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.
31. Johnston PG, Benson AB III, Catalano P et al. Thymidylate synthase protein expression in primary colorectal cancer: Lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003; 21: 815-819.
32. Nishimura T, Newkirk K, Sessions RB et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996; 2: 1859-1865.
33. Shiga H, Heath EI, Rasmussen AA et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5: 4097-4104.
34. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-942.
35. Keam B, Han SW, Ham H et al. Pharmacogenomic prediction of response in advanced gastric cancer (AGC) patients receiving 5-fluorouracil (FU)/ leucovorin (LV)/oxaliplatin (OX) as a first-line palliative chemotherapy. Proc Am Soc Clin Oncol 2006; 23: 206.
36. Bamshad M. Genetic influences on health. JAMA 2005; 294: 937-946.